Search for a trial

A Phase I, drug-drug interaction study between oral doses of GLPG1205 and an OCT2 probe substrate (metformin) or a BCRP probe substrate (rosuvastatin) in healthy male subjects

PrimaryTo assess the effect of GLPG1205 on the single dose pharmacokinetics (PK) of an OCT2 probe substrate, metformin, in healthy male subjects.To assess the effect of GLPG1205 on the single dose pharmacokinetics (PK) of a BCRP probe substrate,…

A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled with Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin

Primary ObjectivesIn patients with primary hypercholesterolemia and high cardiovascular risk with LDL-C >=100 mg/dL (2.59 mmol/L) and <=160 mg/dL (4.14 mmol/L), to evaluate:1)at the end of Phase I, the additional LDL-C percentage…

Rosuvastatin use to improve the coagulation profile in patients with venous thrombosis: The STAtins Reduce Thrombophilia (START) Study

To understand why statins are able to decrease the risk of developing venous thrombosis, by analyzing whether statins can influence pathways that inhibit coagulation.

A Multi-Centre, Randomised, Double Blind, Placebo Controlled, Parallel Group Study of TA 8995 in Patients with Mild Dyslipidaemia, Alone and In Combination with Statin Therapy

The primary objective of this study is to evaluate the efficacy of different doses of TA 8995, a cholesteryl ester transfer protein (CETP) inhibitor, on the elevation of high density lipoprotein cholesterol (HDL C) and reduction of low density…

A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination with Atorvastatin, Simvastatin, and Rosuvastatin in Patients with Hypercholesterolemia or Low HDL-C.

The primary objective of this study is to determine whether LY2484595, administered incombination with atorvastatin for 12 weeks to patients with hypercholesterolemia or low HDL-C, will significantly increase mean HDL-C and decrease mean LDL-C from…

The Effect of Rosuvastatin on Immune Activation Markers in Treatment-naïve HIV-Positive Patients; a Randomized Placebo-Controlled Trial

Primary Objective: to investigate the effect of rosuvastatin 20 mg qd on subsequent immune activation markers in treatment-naïve HIV-patients: circulating LPS (LAL assay), TLR mRNA expression in whole blood, circulating IL-6, D-dimer, hsCRP, CD38…

Short term statin treatment and endothelial dysfunction due to ischemia and reperfusion injury

To study the protective effect of pretreatment (both 3 day and 7 day) with rosuvastatin and atorvastatin on flow mediated dilation after 15 minutes ischemia and 15 minutes reperfusion.

HEART OUTCOMES PREVENTION EVALUATION (HOPE) - 3

The HOPE-3 trial will evaluate the effects of lipid modification with rosuvastatin and of blood pressure lowering with candesartan/hydrochlorothiazide (HCT) and their combination in a wide range of middle aged people, who are at average risk for…

Does cafeine reduce rosuvastatin-induced protection against ischemia-reperfusion injury?

Primary Objective: The objective of this project is to explore the role of adenosine receptor stimulation in the protective effect of rosuvastatin against ischemia-reperfusion injury after ischemic exercise of the forearm.Secondary Objective(s):…

The persisting effect of episodic exercise training in patients with chronic heart failure.

Determine the prolonged effect of a 12 week physical exercise program in congestive heart failure patients.

Systemic effects of mild renal insufficiency: the relation between forearm blood flow and ADMA.

The results of this study will give better insights in the role of ADMA in the development of systemic endothelial dysfunction.

Is augmentation of PORH by rosuvastatin adenosine-receptor mediated?

To study the influence of caffeine on post occlusive reactive hyperaemia before and after 7 days treatment with rosuvastatin.

ADMA and renal endothelial dysfunction: de effects of ARB and/or statins in hypertensive patients with mild renal insufficiency

The results of this study will give better insights in the role of ADMA in the development of systemicendothelial dysfunction and the relation with mild renal insufficiency.

Systemic effects in patients with COPD; training or treatment

To study the possible relation between systemic inflammation and oxidative stress and muscle breakdown using pharmacological interventions.

A Randomized, Double-blind, Placebo-controlled, Multi-center, Cross-over Study of Rosuvastatin in Children and Adolescents (aged 6 to <18 years) with Homozygous Familial Hypercholesterolemia (HoFH)

To assess the efficacy of rosuvastatin 20 mg on low-density lipoprotein cholesterol (LDL-C), compared to placebo, after 6 weeks of treatment in pediatric patients with HoFH.